PK of Multiple Repeated Doses of Intranasal Naloxone

Phase 1, randomised, open-label trial of naloxone in opioid overdose (3 arms), sponsored by Food and Drug Administration. Primary endpoints: First Timepoint When There is a Higher Naloxone Plasma Concentration in the 4 Naloxone Dose Arm (1 Every 2.5 Min) Compared to the 2 Naloxone Dose Arm (1 Every 2.5 Min) and First Timepoint When There is a Higher Naloxone Plasma Concentration in the 4 Naloxone Dose Arm (2 Doses Every 2.5 Min) Compared to the 2 Naloxone Dose Arm (1 Every 2.5 Min). Started Mar 2021; status: completed.